Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Augmented R-ICE for Aggressive B-Cell NHL
NCT00588094Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2003
- Primary completion
- Mar 2010
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab, ifosfamide, carboplatin, etoposide in B-cell non-Hodgkin lymphoma, sponsored by Memorial Sloan Kettering Cancer Center. Started Oct 2003; status: completed.
02
Drugs
rituximabifosfamidecarboplatinetoposide
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT00588094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00588094.